First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2L advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial

Sadeleştirilmiş öğe sayfası
dc.contributor.authorYap, Y\\-S.
dc.contributor.authorIm, S\\-A.
dc.contributor.authorLu, Y\\-S.
dc.contributor.authorAzim, H. A.
dc.contributor.authorEralp, Y.
dc.contributor.authorKanakasetty, G. B.
dc.contributor.authorAbdel\\-Razeq, H.
dc.contributor.authorZhukova, L.
dc.contributor.authorThuerigen, A.
dc.contributor.authorAlfaro, T. Delgar
dc.contributor.authorWu, J.
dc.contributor.authorGao, M.
dc.contributor.authorEl Saghir, N. S.
dc.date.accessioned2025-10-16T15:14:20Z
dc.date.issued2023
dc.description.abstractAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, DEC 01-03, 2023
dc.identifier.otherWOS:001122475400061
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6136
dc.publisherELSEVIER
dc.sourceANNALS OF ONCOLOGY
dc.titleFirst-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2L advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS